Shakti Singh

Dr. Shakti Singh

Infectious Diseases, The Lundquist Institute, Torrance, California, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2021 in Nature
Verified
Journal Article
Closed access
PDF file
KOKyla S. Ost
Kyla S. Ost
TOTeresa O'Meara
Teresa O'Meara
WSW. Zac Stephens
W. Zac Stephens
TCTyson Chiaro
Tyson Chiaro
HZHaoyang Zhou
Haoyang Zhou
JRJune L. Round
June L. Round

29 September 2023 in Science
Verified
Journal Article
Closed access
DSDarian J. Santana
Darian J. Santana
JAJuliet A. E. Anku
Juliet A. E. Anku
GZGuolei Zhao
Guolei Zhao
RZRobert Zarnowski
Robert Zarnowski
CJChad J. Johnson
Chad J. Johnson
TOTeresa O'Meara
Teresa O'Meara
Candida auris is an emerging fungal pathogen responsible for health care–associated outbreaks that arise from persistent surface and skin colonization. We characterized the arsenal of adhesins used by C. auris and discovered an uncharacterized adhesin, Surface Colonization Factor (Scf1), and a conserved adhesin, Iff4109, that are essential for the colonization of inert surfaces and mammalian hosts. SCF1 is apparently specific to C. auris , and its expression mediates adhesion to inert and biological surfaces across isolates from all five clades. Unlike canonical fungal adhesins, which function through hydrophobic interactions, Scf1 relies on exposed cationic residues for surface association. SCF1 is required for C. auris biofilm formation, skin colonization, virulence in systemic infection, and colonization of inserted medical devices.

5 August 2019 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
Shakti SinghShakti Singh
Shakti Singh
PUPriya Uppuluri
Priya Uppuluri
ZMZeinab Mamouei
Zeinab Mamouei
AAAbdullah Alqarihi
Abdullah Alqarihi
HEHana Elhassan
Hana Elhassan
Ashraf IbrahimAshraf Ibrahim
Ashraf Ibrahim
Candida auris is an emerging, multi-drug resistant, health care-associated fungal pathogen. Its predominant prevalence in hospitals and nursing homes indicates its ability to adhere to and colonize the skin, or persist in an environment outside the host—a trait unique from other Candida species. Besides being associated globally with life-threatening disseminated infections, C. auris also poses significant clinical challenges due to its ability to adhere to polymeric surfaces and form highly drug-resistant biofilms. Here, we performed bioinformatic studies to identify the presence of adhesin proteins in C. auris, with sequence as well as 3-D structural homologies to the major adhesin/invasin of C. albicans, Als3. Anti-Als3p antibodies generated by vaccinating mice with NDV-3A (a vaccine based on the N-terminus of Als3 protein formulated with alum) recognized C. auris in vitro, blocked its ability to form biofilms and enhanced macrophage-mediated killing of the fungus. Furthermore, NDV-3A vaccination induced significant levels of C. auris cross-reactive humoral and cellular immune responses, and protected immunosuppressed mice from lethal C. auris disseminated infection, compared to the control alum-vaccinated mice. The mechanism of protection is attributed to anti-Als3p antibodies and CD4+ T helper cells activating tissue macrophages. Finally, NDV-3A potentiated the protective efficacy of the antifungal drug micafungin, against C. auris candidemia. Identification of Als3-like adhesins in C. auris makes it a target for immunotherapeutic strategies using NDV-3A, a vaccine with known efficacy against other Candida species and safety as well as efficacy in clinical trials. Considering that C. auris can be resistant to almost all classes of antifungal drugs, such an approach has profound clinical relevance. Candida auris has emerged as a major health concern to hospitalized patients and nursing home subjects. C. auris strains display multidrug resistance to current antifungal therapy and cause lethal infections. We have determined that C. auris harbors homologs of C. albicans Als cell surface proteins. The C. albicans NDV-3A vaccine, harboring the N-terminus of Als3p formulated with alum, generates cross-reactive antibodies against C. auris clinical isolates and protects neutropenic mice from hematogenously disseminated C. auris infection. Importantly, the NDV-3A vaccine displays an additive protective effect in neutropenic mice when combined with micafungin. Due to its proven safety and efficacy in humans against C. albicans infection, our studies support the expedited testing of the NDV-3A vaccine against C. auris in future clinical trials.

18 January 2021 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
SSSameh Soliman
Sameh Soliman
CBClara Baldin
Clara Baldin
Yiyou GuYiyou Gu
Yiyou Gu
Shakti SinghShakti Singh
Shakti Singh
TGTeclegiorgis Gebremariam
Teclegiorgis Gebremariam
Ashraf IbrahimAshraf Ibrahim
Ashraf Ibrahim

21 February 2020 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
SASondus Alkhazraji
Sondus Alkhazraji
TGTeclegiorgis Gebremariam
Teclegiorgis Gebremariam
AAAbdullah Alqarihi
Abdullah Alqarihi
Yiyou GuYiyou Gu
Yiyou Gu
ZMZeinab Mamouei
Zeinab Mamouei
Ashraf IbrahimAshraf Ibrahim
Ashraf Ibrahim
There are limited treatment options for immunosuppressed patients with lethal invasive fungal infections due to Fusarium and Scedosporium . Manogepix (MGX; APX001A) is a novel antifungal that targets the conserved Gwt1 enzyme required for localization of glycosylphosphatidylinositol-anchored mannoproteins in fungi. We evaluated the in vitro activity of MGX and the efficacy of the prodrug fosmanogepix (APX001) in immunosuppressed murine models of hematogenously disseminated fusariosis and pulmonary scedosporiosis.

22 December 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
KIKali R. Iyer
Kali R. Iyer
KCKaddy Camara
Kaddy Camara
MDMartin Daniel-Ivad
Martin Daniel-Ivad
RTRichard Trilles
Richard Trilles
SPSheila M. Pimentel-Elardo
Sheila M. Pimentel-Elardo
LCLeah E. Cowen
Leah E. Cowen
Candida auris is an emerging fungal pathogen that exhibits resistance to multiple drugs, including the most commonly prescribed antifungal, fluconazole. Here, we use a combinatorial screening approach to identify a bis-benzodioxolylindolinone (azoffluxin) that synergizes with fluconazole against C. auris. Azoffluxin enhances fluconazole activity through the inhibition of efflux pump Cdr1, thus increasing intracellular fluconazole levels. This activity is conserved across most C. auris clades, with the exception of clade III. Azoffluxin also inhibits efflux in highly azole-resistant strains of Candida albicans, another human fungal pathogen, increasing their susceptibility to fluconazole. Furthermore, azoffluxin enhances fluconazole activity in mice infected with C. auris, reducing fungal burden. Our findings suggest that pharmacologically targeting Cdr1 in combination with azoles may be an effective strategy to control infection caused by azole-resistant isolates of C. auris.